Alpine Immune Sciences Future Growth

Future criteria checks 2/6

Alpine Immune Sciences's earnings are forecast to decline at 9.9% per annum while its annual revenue is expected to grow at 34.2% per year. EPS is expected to decline by 11% per annum. Return on equity is forecast to be -78.4% in 3 years.

Key information

-9.9%

Earnings growth rate

-11.0%

EPS growth rate

Biotechs earnings growth	42.2%
Revenue growth rate	34.2%
Future return on equity	-78.4%
Analyst coverage	Good
Last updated	17 May 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:34LA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	10	-149	-173	-150	7
12/31/2025	20	-110	-140	-113	8
12/31/2024	18	-97	-96	-91	7
3/31/2024	57	-37	-81	-81	N/A
12/31/2023	59	-32	-79	-79	N/A
9/30/2023	31	-57	-77	-77	N/A
6/30/2023	29	-59	-78	-77	N/A
3/31/2023	26	-64	-76	-75	N/A
12/31/2022	30	-58	-44	-44	N/A
9/30/2022	32	-54	-42	-42	N/A
6/30/2022	32	-54	4	5	N/A
3/31/2022	34	-47	6	6	N/A
12/31/2021	23	-50	-15	-15	N/A
9/30/2021	25	-42	-10	-10	N/A
6/30/2021	18	-34	-46	-45	N/A
3/31/2021	11	-33	23	24	N/A
12/31/2020	9	-28	29	30	N/A
9/30/2020	5	-28	33	34	N/A
6/30/2020	3	-33	28	29	N/A
3/31/2020	3	-35	-35	-34	N/A
12/31/2019	2	-42	-36	-35	N/A
9/30/2019	1	-47	-39	-39	N/A
6/30/2019	1	-48	-36	-36	N/A
3/31/2019	0	-44	-35	-35	N/A
12/31/2018	1	-36	-29	-28	N/A
9/30/2018	1	-30	-25	-25	N/A
6/30/2018	1	-15	-23	-22	N/A
3/31/2018	1	-11	-19	-19	N/A
12/31/2017	2	-8	N/A	-17	N/A
9/30/2017	2	-5	N/A	-13	N/A
6/30/2017	3	-7	N/A	-9	N/A
3/31/2017	3	-3	N/A	-6	N/A
12/31/2016	3	-1	N/A	-4	N/A
12/31/2015	0	0	N/A	5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 34LA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 34LA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 34LA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 34LA's revenue (34.2% per year) is forecast to grow faster than the German market (5.1% per year).

High Growth Revenue: 34LA's revenue (34.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 34LA is forecast to be unprofitable in 3 years.

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/05/20 22:53
End of Day Share Price	2024/05/20 00:00
Earnings	2024/03/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alpine Immune Sciences, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Gao Yi Chen	Berenberg
Vamil Divan	Guggenheim Securities, LLC
Joseph Pantginis	H.C. Wainwright & Co.

Alpine Immune Sciences Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

Alpine Immune Sciences Files Form 15

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P TMI Index

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.28 loss in 1Q 2023)

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Alpine Immune Sciences, Inc Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

Full year 2023 earnings released: US$0.64 loss per share (vs US$1.73 loss in FY 2022)

Alpine Immune Sciences, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Insufficient new directors

Insufficient new directors

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $149.9968 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

Alpine Immune Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Alpine Immune Sciences, Inc. Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis

New major risk - Share price stability

Alpine Immune Sciences, Inc. Announces Appointment of Wolfgang Dummer as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)

Second quarter 2023 earnings released: US$0.27 loss per share (vs US$0.60 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.25 loss in 1Q 2022)

Full year 2022 earnings released: US$1.73 loss per share (vs US$1.98 loss in FY 2021)

Insufficient new directors

Insufficient new directors

Alpine Immune Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. Provides Clinical Updates for Its Two Wholly Owned Programs, ALPN-303 and davoceticept

Second quarter 2022 earnings released: US$0.60 loss per share (vs US$0.46 loss in 2Q 2021)

Alpine Immune Sciences, Inc. Announces Board Changes

Alpine Immune Sciences Appoints Andrew S. Sandler as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

First quarter 2022 earnings released: US$0.25 loss per share (vs US$0.45 loss in 1Q 2021)

Alpine Immune Sciences, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Alpine Immune Sciences Announces Oral Presentation at the 2022 AACR Annual Meeting

Insufficient new directors

Alpine Immune Sciences, Inc. announced that it expects to receive $15 million in funding from Horizon Therapeutics Public Limited Company

Insufficient new directors

Third quarter 2021 earnings released: US$0.55 loss per share (vs US$0.28 loss in 3Q 2020)

Independent Director recently bought €84k worth of stock

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.53 loss in 2Q 2020)

Alpine Immune Sciences Announces First Patient Dosed in Synergy, Alpn-101 Phase 2 Lupus Clinical Trial and $45 Million in Development Milestones Achieved Under Abbvie Collaboration

Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at 2021 American Society of Clinical Oncology Virtual Annual Meeting

Alpine Immune Sciences, Inc. Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting

First quarter 2021 earnings released: US$0.45 loss per share (vs US$0.30 loss in 1Q 2020)

Full year 2020 earnings released: US$1.34 loss per share (vs US$2.28 loss in FY 2019)

Alpine Immune Sciences, Inc. to Report Q4, 2020 Results on Mar 18, 2021

Alpine Immune Sciences, Inc. Announces Executive Changes

New 90-day high: €11.80

Alpine Immune Sciences Appoints Natasha A. Hernday to its Board of Directors

New 90-day high: €7.70

Independent Director recently bought €68k worth of stock

Third quarter 2020 earnings released: US$0.28 loss per share

Revenue misses expectations

Alpine Immune Sciences, Inc. to Report Q3, 2020 Results on Nov 12, 2020

First half earnings released

Alpine Immune Sciences, Inc. announced that it has received $60.000012 million in funding from a group of investors

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources